Cargando…
Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report
INTRODUCTION: Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. Several novel therapeutic strategies have been developed to prolong the survival of patients with advanced HCC. However, therapeutic decision-making biomarkers owing to the extensive heterogeneity of HCC. Next-...
Autores principales: | Gu, Yangjun, Xiao, Min, Chen, Zhitao, Li, Qiyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467267/ https://www.ncbi.nlm.nih.gov/pubmed/37655101 http://dx.doi.org/10.3389/fonc.2023.1196211 |
Ejemplares similares
-
Association between gut microbiota and hepatocellular carcinoma from 2011 to 2022: Bibliometric analysis and global trends
por: Chen, Zhitao, et al.
Publicado: (2023) -
Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary
por: Palma, Norma A., et al.
Publicado: (2014) -
Case report: Prompt response to radiotherapy and chemotherapy combined with crizotinib in gingival sarcomatoid squamous cell carcinoma with MET 14 mutation
por: Sun, Zhenhua, et al.
Publicado: (2022) -
Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells
por: Schroeder, Rebecca D., et al.
Publicado: (2017) -
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program
por: Aparicio, Thomas, et al.
Publicado: (2021)